Skip to main content
Premium Trial:

Request an Annual Quote

Pyrosequencing Posts Fallen Revenue, Narrowed Loss in Q4

NEW YORK, Feb. 20 - Pyrosequencing today reported a slight decrease in total revenue, curtailed R&D spending, and a narrowed net loss.

 

Total receipts for the period ended Dec. 31 were $3.9 million compared with $4.3 million for the same time last year, Pyrosequencing said. The company attributed the decline to poor exchange rates between the Swedish krona and the US dollar and euro.

 

R&D spending in the quarter, meantime, was cut to $30.3 million from $42.8 million year over year. As a result, net loss narrowed to $5.5 million, or $.16 per share, from $6.2 million, or $.18 per share, in the fourth quarter 2001.

 

Pyrosequencing said it had roughly $54 million in cash, cash equivalents, and investments in high-grade debt securities as of Dec. 31.

 

Click here for more information.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.